2016 Fiscal Year Final Research Report
Development of novel treatment for GVHD following hematopoietic cell transplantation using M2 macrophage
| Project/Area Number |
26461443
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Mie University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
TOYODA Hidemi 三重大学, 医学部附属病院, 講師 (60525327)
|
|---|
| Research Collaborator |
HANAKI Ryo 三重大学, 医学部附属病院, 医員 (40780408)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | 移植片対宿主病 / マクロファージ / 単球 / 造血細胞移植 |
|---|
| Outline of Final Research Achievements |
Treatment of chronic GVHD, which influences prognosis after hematopoietic cell transplantation, has not yet been established. We have previously demonstrated that anti-inflammatory monocytes produce IL-10 in chronic GVHD and are involved in the repair of damaged target organs. There are inflammatory M1 type and anti - inflammatory type M2 type in macrophages. Using this M2 macrophage, a novel treatment for GVHD has developed. Two types of macrophages M1 and M2 were induced by culturing them with cytokines of GM-CSF and M-CSF from mouse bone marrow cells. In murine GVHD model, M2 macrophages reduced lethal GVHD and improved survival rate. Future clinical application has been expected.
|
| Free Research Field |
造血細胞移植
|
